Yong Kim

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus

J. Park, K. Min, S. Baik, 2020, Diabetes & metabolism journal.

Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results

Nicole M. Armstrong, G. Diaz, R. Giugliani, 2022, Orphanet Journal of Rare Diseases.

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults

R. Lachmann, G. Diaz, M. Wasserstein, 2023, Orphanet Journal of Rare Diseases.

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

B. Thurberg, J. Hennermann, P. Mabe, 2023, Orphanet Journal of Rare Diseases.